Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.77 0.40 −6.48%
Market cap
$170.3M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(132.91%) (69.52%) (61.52%) (205.16%)

+8 more TTM periods

Piotroski F-Score
— 2 1 1
ROA
(44.91%) (32.50%) (31.45%) (67.76%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(61.77%) (42.69%) (41.10%) (215.83%)
Average Days of Receivables
— 32.39 0.00 2.09
Free Cash Flow per Share
(2.02) (2.40) (5.18) (6.23)
Free Cash Flow
(52.32) (59.16) (66.48) (73.68)
Other line items

Show all line items

Columns are period end dates